Beyond Air Awarded National Group Purchasing Agreement For Inhaled Nitric Oxide Therapy With U.S. Group Purchasing Organization

Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system.

This new agreement builds on Beyond Air's existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of healthcare providers in the United States.